Enterprise Value
59.28M
Cash
246.9M
Avg Qtr Burn
-17.47M
Short % of Float
5.00%
Insider Ownership
3.72%
Institutional Own.
71.74%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IVX-A12 (RSV+hMPV) Details Respiratory syncytial virus, Human metapneumovirus, Vaccine | Phase 2 Data readout | |
IVX-121 Details Respiratory syncytial virus | Phase 1/2 Update | |
IVX-411 Details COVID-19 | Failed Discontinued |